ArticleThe New England journal of medicine2015
The FDA and genomic tests--getting regulation right.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Understanding Genetic Screening: Harnessing Health Information to Prevent Disease Risks.International journal of medical sciences · 2025Review
- Artificial intelligence and urology: ethical considerations for urologists and patients.Nature reviews. Urology · 2024Review
- Polygenic Scores in the Direct-to-Consumer Setting: Challenges and Opportunities for a New Era in Consumer Genetic Testing.Journal of personalized medicine · 2023Review
- Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements.The EPMA journal · 2022Review
- Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes.The EPMA journal · 2021Review
- Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study Indicate What Laboratory-Developed Test Regulation by the US Food and Drug Administration (FDA) Could Look Like.The Journal of molecular diagnostics : JMD · 2021Review
- The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.Current opinion in lipidology · 2021Review
- Clinical metagenomics for infectious corneal ulcers: Rags to riches?The ocular surface · 2020Article
- A decade of clinical development of PARP inhibitors in perspective.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Developmental roadmap for antimicrobial susceptibility testing systems.Nature reviews. Microbiology · 2019Review
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).Annals of oncology : official journal of the European Society for Medical Oncology · 2018Article
- How should costs and cost-effectiveness be considered in prenatal genetic testing?Seminars in perinatology · 2018Review
- FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine.NPJ genomic medicine · 2018Article
- Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.The oncologist · 2017Article
- Precision reproductive medicine: multigene panel testing for infertility risk assessment.Journal of assisted reproduction and genetics · 2017Review
- Article
- Acquiring evidence for precision prostate cancer care.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.Journal of the National Comprehensive Cancer Network : JNCCN · 2017Article
- EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.International journal of technology assessment in health care · 2017Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.